CG Oncology (NASDAQ:CGON) Price Target Raised to $81.00

CG Oncology (NASDAQ:CGON) had its price objective lifted by Royal Bank Of Canada from $79.00 to $81.00 in a report published on Monday morning, Marketbeat reports. The brokerage currently has an outperform rating on the stock.

A number of other analysts have also weighed in on CGON. Piper Sandler upped their target price on shares of CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a research note on Friday, January 16th. JPMorgan Chase & Co. upped their target price on shares of CG Oncology from $65.00 to $91.00 and gave the stock an “overweight” rating in a research note on Friday, April 17th. HC Wainwright upped their target price on shares of CG Oncology from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Wall Street Zen lowered shares of CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Wedbush upped their target price on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, CG Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $81.27.

CG Oncology Stock Performance

CGON stock opened at $74.00 on Monday. The company’s 50 day moving average price is $66.77 and its 200 day moving average price is $53.68. CG Oncology has a fifty-two week low of $23.32 and a fifty-two week high of $74.35. The firm has a market capitalization of $6.53 billion, a price-to-earnings ratio of -31.76 and a beta of 0.41.

CG Oncology (NASDAQ:CGON) last released its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million for the quarter, compared to analysts’ expectations of $0.45 million. Equities analysts forecast that CG Oncology will post -2.77 EPS for the current fiscal year.

Insider Buying and Selling

In other CG Oncology news, Director James Mulay sold 15,600 shares of the stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $73.01, for a total value of $1,138,956.00. Following the transaction, the director directly owned 15,600 shares in the company, valued at $1,138,956. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CG Oncology

Hedge funds have recently added to or reduced their stakes in the stock. Candriam S.C.A. increased its stake in CG Oncology by 35.9% in the third quarter. Candriam S.C.A. now owns 1,037,892 shares of the company’s stock valued at $41,806,000 after purchasing an additional 274,312 shares during the last quarter. JPMorgan Chase & Co. increased its stake in CG Oncology by 321.3% in the third quarter. JPMorgan Chase & Co. now owns 227,879 shares of the company’s stock valued at $9,179,000 after purchasing an additional 173,785 shares during the last quarter. Vanguard Group Inc. increased its stake in CG Oncology by 11.4% in the third quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after purchasing an additional 670,770 shares during the last quarter. Mangrove Partners IM LLC increased its stake in CG Oncology by 21.0% in the third quarter. Mangrove Partners IM LLC now owns 671,692 shares of the company’s stock valued at $27,056,000 after purchasing an additional 116,575 shares during the last quarter. Finally, Sivik Global Healthcare LLC purchased a new position in CG Oncology in the fourth quarter valued at approximately $1,453,000. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

CG Oncology News Summary

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and $100 price target on CG Oncology, signaling continued confidence in the company’s long-term opportunity despite near-term losses. HC Wainwright analyst note
• Positive Sentiment: Other recent analyst actions also leaned constructive, including a new $81 target from RBC, a Buy rating from Truist, and a new $96 target from JPMorgan, which may be helping sentiment. RBC price target article
• Neutral Sentiment: HC Wainwright lowered earnings estimates for 2026–2029, reflecting expectations for larger losses in the near term, but it also raised its FY2030 EPS estimate to $6.77, implying a potentially meaningful long-term earnings ramp. HC Wainwright earnings estimate update
• Neutral Sentiment: CG Oncology’s recent presentation at the Bank of America Global Healthcare Conference and its presence at the AUA Annual Meeting keep investor attention on its clinical and commercial progress, but these items are not direct catalysts by themselves. Conference presentation transcript

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.